168 related articles for article (PubMed ID: 17632316)
1. Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis.
Kumar Y; Gurusamy K; Pamecha V; Davidson BR
Pancreas; 2007 Aug; 35(2):114-9. PubMed ID: 17632316
[TBL] [Abstract][Full Text] [Related]
2. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
Kumar Y; Tapuria N; Kirmani N; Davidson BR
Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
[TBL] [Abstract][Full Text] [Related]
3. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions.
Cerwenka H; Aigner R; Bacher H; Werkgartner G; el-Shabrawi A; Quehenberger F; Mischinger HJ
Anticancer Res; 1999; 19(1B):849-51. PubMed ID: 10216504
[TBL] [Abstract][Full Text] [Related]
4. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
[TBL] [Abstract][Full Text] [Related]
5. Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer.
Oremek GM; Eigenbrodt E; Rädle J; Zeuzem S; Seiffert UB
Anticancer Res; 1997; 17(4B):3031-3. PubMed ID: 9329593
[TBL] [Abstract][Full Text] [Related]
6. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
[TBL] [Abstract][Full Text] [Related]
7. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer.
Hardt PD; Ngoumou BK; Rupp J; Schnell-Kretschmer H; Kloer HU
Anticancer Res; 2000; 20(6D):4965-8. PubMed ID: 11326648
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis.
Goonetilleke KS; Mason JM; Siriwardana P; King NK; France MW; Siriwardena AK
Pancreas; 2007 Apr; 34(3):318-24. PubMed ID: 17414054
[TBL] [Abstract][Full Text] [Related]
9. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.
Schneider J; Schulze G
Anticancer Res; 2003; 23(6D):5089-93. PubMed ID: 14981971
[TBL] [Abstract][Full Text] [Related]
10. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer.
Schulze G
Anticancer Res; 2000; 20(6D):4961-4. PubMed ID: 11326647
[TBL] [Abstract][Full Text] [Related]
11. Tumor M2-pyruvate kinase and pancreatic cancer.
Cerwenka H
Pancreas; 2008 Aug; 37(2):221-2; author reply 222. PubMed ID: 18665086
[No Abstract] [Full Text] [Related]
12. Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer.
Lüftner D; Mazurek S; Henschke P; Mesterharm J; Schildhauer S; Geppert R; Wernecke KD; Possinger K
Anticancer Res; 2003; 23(2A):991-7. PubMed ID: 12820337
[TBL] [Abstract][Full Text] [Related]
13. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer.
Ervens J; Fuchs H; Niemann VT; Hoffmeister B
J Craniomaxillofac Surg; 2008 Mar; 36(2):89-94. PubMed ID: 18243718
[TBL] [Abstract][Full Text] [Related]
14. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK.
Schneider J; Bitterlich N; Schulze G
Anticancer Res; 2005; 25(3A):1507-15. PubMed ID: 16033052
[TBL] [Abstract][Full Text] [Related]
15. Tumor marker M2-pyruvate-kinase in differential diagnosis of chronic pancreatitis and pancreatic cancer.
Novotný I; Dítĕ P; Dastych M; Záková A; Trna J; Novotná H; Nechutová H
Hepatogastroenterology; 2008; 55(85):1475-7. PubMed ID: 18795715
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
Nisman B; Yutkin V; Nechushtan H; Gofrit ON; Peretz T; Gronowitz S; Pode D
Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
[TBL] [Abstract][Full Text] [Related]
17. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data].
Ewald N; Toepler M; Akinci A; Kloer HU; Bretzel RG; Hardt PD
Z Gastroenterol; 2005 Dec; 43(12):1313-7. PubMed ID: 16315127
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma.
Li YG; Zhang N
Dig Liver Dis; 2009 Aug; 41(8):605-8. PubMed ID: 19168405
[TBL] [Abstract][Full Text] [Related]
19. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.
Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312
[TBL] [Abstract][Full Text] [Related]
20. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma.
Ugurel S; Bell N; Sucker A; Zimpfer A; Rittgen W; Schadendorf D
Int J Cancer; 2005 Dec; 117(5):825-30. PubMed ID: 15957165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]